Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dopamine chemoreflex blockade study in fibrotic interstitial lung disease
ACTRN12621000049875Phase 4Completed
- Sponsor
- The University of Auckland
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of dopamine in interstitial lung disease (ILD) (2 arms), sponsored by The University of Auckland. Primary endpoints: Dyspnoea intensity, Exercise endurance time and 1 more. Started Mar 2024; status: completed.
02
Drugs
dopamine
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on ACTRN12621000049875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000049875.